Achromatopsia, ACHM (Day Blindness) in Dogs

  • Occurrence: very rare
  • Location of illness: Back/Tail
Author: Dr. med. vet. Gisa Löwe | Last modified: 06.11.2025

Achromatopsia (ACHM), also known as day blindness or hemeralopia, is a rare, congenital retinal disease in dogs. This condition involves a malfunction of the cones in the retina, while the rods function normally. The cones are responsible for color vision and sharp vision in daylight, while the rods are responsible for twilight and night vision.

The most important facts at a glance

Achromatopsia (ACHM) or day blindness is a congenital, non-progressive retinal disease in dogs caused by a malfunction of the cones in the retina. Affected animals suffer from severely impaired vision in daylight and a lack of color vision, while their vision in twilight and darkness is relatively normal.

The disease is inherited in an autosomal recessive manner and is based on mutations in genes such as CNGB3 and CNGA3, which are necessary for the function of the cones. Certain dog breeds such as Alaskan Malamute, German Shepherd and Australian Shepherd are particularly affected.

Characteristic symptoms include photophobia, increased blinking in bright light, insecure behavior in sunny environments, and significantly better vision in twilight. The diagnosis is made through clinical observation, specialized ophthalmological examinations such as electroretinography, and genetic tests.

Although there is currently no cure available, symptomatic measures such as light protection, environmental adjustments, and special training can significantly improve the quality of life of affected dogs. Promising research approaches in gene therapy are showing initial success in restoring cone function, but are still in the experimental stage.

The prognosis for life expectancy is good, as the disease is not progressive. Affected dogs can adapt well to their visual impairment and lead a largely normal life with appropriate support. Genetic tests and responsible breeding programs are crucial to reduce the spread of the disease.

Causes

  • Genetically caused by inheritance of a defective gene that impairs the function of the cones in the retina.
  • The specific genetic mutations that lead to achromatopsia can vary depending on the breed.

In contrast to healthy dogs, which have dichromatic color vision (blue-yellow spectrum), dogs with achromatopsia cannot distinguish colors and see their environment exclusively in grayscale. In addition, their visual acuity in daylight is severely limited, even to functional Blindness. In low light, however, affected dogs can see relatively well, as the intact rods take over visual perception.

Achromatopsia in dogs is a genetically determined disease based on mutations in specific genes that are essential for the function of the cones in the retina. Inheritance is autosomal recessive, meaning that a dog must inherit two defective gene copies (one from each parent) to develop the disease. Carriers with only one defective gene copy do not show clinical symptoms but can pass the defective gene on to their offspring. The disease manifests itself in early puppyhood when the animals are increasingly exposed to daylight. Achromatopsia is not progressive – this means that vision neither worsens nor improves over the course of life, unless secondary eye diseases are added.

Scientific research has identified several specific gene mutations that can cause achromatopsia. The most common affect the CNGB3 and CNGA3 genes, which encode proteins necessary for signal transmission in the cones. For example, a deletion in the CNGB3 gene has been detected in the Alaskan Malamute, while mutations in the CNGA3 gene have been documented in the German Shepherd.

The prevalence of achromatopsia varies depending on the dog breed and geographic region. In addition to the Alaskan Malamute and German Shepherd, Australian Shepherds, Labrador Retrievers, and some other breeds are particularly affected. In certain breeding lines, the frequency of carriers can be considerable, which underlines the importance of genetic screening programs in responsible dog breeding.

Symptoms

Rare symptoms:

Typical signs of achromatopsia in dogs are:

  • Photophobia (sensitivity to light) : The animals show clear discomfort in bright lighting. They squint their eyes, blink predominantly, and avoid direct sunlight.
  • Insecure behavior during the day: In strong daylight or bright interiors, orientation difficulties can occur. The dog appears anxious, stumbles over obstacles, or refuses to walk on unfamiliar terrain.
  • Increased blinking and squinting (blepharospasm): The eyelids are reflexively pressed together to reduce glare.
  • Limited color and detail perception: From a human perspective, this is hardly noticeable, but owners sometimes notice that their dog reacts less to certain colored objects in daylight.
  • Behavioral changes: Affected dogs are often much more relaxed and confident in dark environments than in bright light.

The symptoms usually appear in young dogs when they start walking and are increasingly exposed to sunlight.

Diagnosis

  • The diagnosis is often made by observing the dog’s behavior in different lighting conditions and a thorough eye examination.
  • Specialized tests such as electroretinography (ERG) can be performed to check the function of the cones in the retina.
  • Genetic tests can be used to identify the specific mutation, if available.

The diagnosis of achromatopsia requires a systematic approach that includes both clinical observations and specialized ophthalmological examinations. The first suspicion usually arises from the characteristic Behavioral changes of the dog in different lighting conditions.

A comprehensive anamnesis is the first step in the diagnostic process. The veterinarian asks in detail about the dog’s behavior in different lighting conditions, the age at which the first symptoms appeared, and possible breed predispositions. The general ophthalmological examination may initially appear unremarkable, as the retina often looks normal on macroscopic examination.

Electroretinography (ERG) is the gold standard for diagnosing achromatopsia. This examination measures the electrical responses of the retina to light stimuli. Characteristic of ACHM is a significantly reduced or absent cone-ERG (photopic ERG) with normal or near-normal rod-ERG (scotopic ERG). This examination requires sedation or anesthesia of the dog and should be performed by a specialized veterinary ophthalmologist.

Optical coherence tomography (OCT) enables high-resolution imaging of the retinal layers and can reveal subtle structural changes in the cone layer that are not visible with conventional ophthalmoscopy.

Genetic tests have become increasingly important in recent years. They not only enable confirmation of the diagnosis, but also the identification of carriers, which is of great importance for breeding programs. Specific DNA tests are available for several dog breeds that can detect the known mutations in the CNGB3 or CNGA3 gene.

The differential diagnosis includes other retinal diseases such as progressive retinal atrophy (PRA), congenital stationary Night blindness, or acquired retinal degenerations. In contrast to achromatopsia, PRA is progressive and primarily affects the rods, leading to increasing Night blindness.

 

Therapy

  • There is no cure or specific treatment for achromatopsia.
  • Management includes adapting the dog’s environment to allow for better navigation and safety in daylight.
  • Sunglasses or visual aids may be useful in some cases to reduce glare and increase comfort.

Currently, there is no curative therapy for achromatopsia in dogs. Treatment focuses on symptomatic measures and adapting the environment to improve the quality of life of affected animals.

A central aspect of management is reducing light exposure. This can be achieved through various measures: walks should preferably take place in the early morning or late evening hours or on cloudy days. Curtains or blinds can be used in the house to regulate the light intensity. Special dog goggles (Doggles) with tinted lenses can reduce glare sensitivity in some dogs and make staying outdoors more pleasant, although acclimatization to such aids varies from individual to individual.

The design of the living environment plays an important role. Constant furniture arrangement, avoidance of obstacles, and the use of dimmed, indirect light can make it easier for the dog to orient itself. It is particularly important to secure potential sources of danger such as stairs or water basins.

In the area of ​​behavior modification, special training can help to promote the dog’s other senses. Acoustic and tactile signals can replace visual commands. Consistent routines give the dog security and reduce stress.

The most promising advances in the field of causal therapy are currently being made in gene therapy. In experimental studies, adeno-associated viral vectors (AAV) have been used to introduce functional copies of the CNGB3 or CNGA3 gene into the retina of affected dogs. In some treated animals, a partial restoration of cone function and improved visual performance in daylight has been demonstrated. However, these approaches are still in the research stage and are not yet available for routine clinical use.

Pharmacological interventions that could influence ion transport in defective cones are also being researched, but have not yet reached clinical maturity.

Prognosis and follow-up care

The prognosis for dogs with achromatopsia is generally good in terms of life expectancy, as it is a non-progressive and non-painful condition. Quality of life can be significantly improved through appropriate environmental adjustments and management.

Affected dogs often develop remarkable adaptation strategies and compensate for their visual impairment by increasing the use of other senses. Most lead a largely normal dog life, especially if the diagnosis is made early and appropriate adjustments are made. Studies show that dogs with congenital visual impairments often adapt better than those with acquired deficits.

Follow-up care focuses on regular veterinary check-ups to detect secondary eye problems early. Although achromatopsia itself is not progressive, affected dogs may be predisposed to other eye diseases. Annual ophthalmological examinations are therefore recommended.

Owners should pay attention to Behavioral changes that could indicate additional visual problems or Pain. Continuous adaptation of the environment to the changing needs of the aging dog is important, as older animals may develop additional age-related visual impairments.

For breeders, genetic counseling is an essential part of aftercare. Systematic genetic testing can identify carriers and develop targeted breeding strategies to reduce the spread of the disease. Responsible breeding programs avoid mating two carriers to eliminate the risk of affected offspring.

Psychological support for owners is also important. Dealing with a visually impaired dog can be challenging at first, but with appropriate advice and exchange with other affected dog owners, many hurdles can be overcome.

Prevention

Since achromatopsia is genetically determined, the focus of prevention is on responsible breeding. Affected dogs and their close relatives should be consistently excluded from breeding. Genetic tests enable the identification of carriers even before symptoms occur. For dogs that are already ill, it is about avoiding accidents: walks in bright light should be avoided and preferably taken in the early morning or evening hours. A shady, glare-free living environment and, if necessary, dog sunglasses can increase well-being. Education of breeders and owners is crucial to eradicate the disease from the populations in the long term.

Outlook on current research

Research into achromatopsia in dogs has made significant progress in recent years, particularly in the field of gene therapy. These developments open up new perspectives for future treatment options.

Current research focuses on AAV-mediated gene therapy (adeno-associated virus vectors). Scientists at the University of Pennsylvania and Michigan State University have conducted groundbreaking studies in which functional copies of the CNGB3 gene were introduced into the retina of Alaskan Malamutes with ACHM using viral vectors. The results showed a partial restoration of cone function and improved visual performance in daylight. These successes form the basis for further clinical trials, which may pave the way for an approved therapy.

In parallel, optimized vector systems are being developed to enable more efficient gene transfer and longer-lasting expression of the therapeutic gene. Research is also focusing on the optimal treatment window – initial results suggest that early intervention at a young age offers the best chance of success, before secondary degenerative changes occur in the retina.

In addition to gene therapy, pharmacological approaches are also being explored. Substances that can modulate the disrupted ion channel transport in the cones are showing promising results in preclinical studies. These could serve as a complementary therapy or as an alternative for patients for whom gene therapy is not applicable.

Advances in imaging technology also enable more precise diagnostics and monitoring. High-resolution OCT procedures and adaptive optics allow the visualization of individual photoreceptors and can reveal subtle changes in the retinal structure, which is of great importance for patient selection and therapy monitoring.

Translational research between veterinary and human medicine is becoming increasingly important. Since canine achromatopsia is an excellent model for the corresponding disease in humans, both sides benefit from the findings. Successful therapeutic approaches in dogs can pave the way for similar treatments in humans.

Although these research approaches are promising, it is important to have realistic expectations. The path from experimental studies to clinical application is often long and fraught with challenges. Experts estimate that it could be several years before gene therapy treatments for achromatopsia will be routinely available.

Frequently asked questions (FAQs)

1. How Do I Know if My Dog ​​Has Achromatopsia?

Typical signs are strong blinking or squinting of the eyes in bright light, insecure walking in brightly lit environments, and a seemingly better orientation in twilight or darkness. A definitive diagnosis is made via an ERG examination by a veterinarian (veterinary ophthalmologist).

2. Is Achromatopsia the Same as Color Blindness in Humans?

Answer: not quite. Although the affected dogs lack functional cones, which is similar to a form of total color Blindness. However, they are mainly day-blind because the cones are also responsible for seeing in brightness. They see very poorly or not at all in bright environments.

3. Which Breeds are Particularly Often Affected?

Achromatopsia occurs in various breeds, including Alaskan Malamute, German Shepherd, Australian Shepherd, Labrador Retriever, and some others. The frequency varies depending on the breeding line.

4. Can I Have My Dog ​​Genetically Tested?

Yes, in many cases DNA tests are available. A blood or cheek swab sample can be sent to a specialized laboratory. The result shows whether the dog is a carrier, free, or affected.

5. Is there a Cure for Achromatopsia?

Currently, there is no fully established cure available. Research is being carried out on gene therapies, which are promising in initial studies. However, routine use is not yet available.

6. What Can I Do to Make Everyday Life Easier for My Dog?

Avoid bright light, use shady places, or reduce the lighting intensity. Some dog owners use dog goggles (Doggles) to protect against direct sunlight. A safely designed environment and training (e.g. with acoustic signals) support orientation.

7. Is My Dog ​​Completely Blind?

In bright light, visual performance is very severely reduced, even to (almost) complete Blindness. In a darker environment, on the other hand, affected dogs see relatively normally because the rods are intact.

8. Can My Dog ​​Still Lead a Normal Life?

Yes, with appropriate adaptation (no long stays in bright sunlight, adapted daily routine, possible protective goggles), these dogs can lead a largely normal life. They are often unproblematic as soon as they operate in a less dazzling environment.

9. From What Age Does Achromatopsia Appear in Dogs?

The first symptoms (problems in bright light conditions, photophobia) often appear in the first weeks or months of life, when puppies start spending more time outdoors and in daylight.

10. How Do I Know if it Really is ACHM and not another Eye Disease?

A veterinary ophthalmological examination (including ERG, fundus examination, and possibly genetic test) is the gold standard. A symptom checker (e.g. petsvetcheck.de ) can provide initial clues, but does not replace a clear diagnosis by a specialist.

Content

When to visit the vet?

Home care monitor at home and contact your vet if worse

If the condition worsens / symptoms persist, consult a veterinarian.

Download/Print